MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.060 +0.220 (+3.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
The market is filled with gapping stocks in Wednesday's session. ↗
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Discover the top movers in Wednesday's pre-market session. ↗
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview: Myriad Genetics ↗
 
Via Benzinga
News headline image
Stock Market Today: US Futures Edge Higher As Investors Await Earnings From McDonald's, Uber And Walt Disney ↗
US stock futures rose on Wed. after falling on Thurs. Trump threatened tariffs on imported pharma up to 250%. Bond yields down & Fed may cut rates. 
Via Benzinga
Topics Economy Government World Trade
News headline image
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance ↗
After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics jumped 35.66% to $5.25 after-hours on Tuesday. 
Via Benzinga
Topics Earnings
News headline image
Myriad Genetics (MYGN) Q2 Revenue Up 6% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Top movers in Tuesday's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales were flat year on year at $213.1 million. The company’s full-year... 
Via StockStory
News headline image
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Earnings To Watch: Myriad Genetics (MYGN) Reports Q2 Results Tomorrow
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Tuesday after market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Burning Stock to Target This Week and 2 We Brush Off
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. 
Via StockStory
News headline image
Myriad Genetics Announces New $200 Million Credit Facility
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Why Myriad Genetics (MYGN) Shares Are Falling Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 3.8% in the afternoon session after weakness in the healthcare sector became pronounced following a poor sales report from a key... 
Via StockStory
Topics Artificial Intelligence Lawsuit
News headline image
3 Volatile Stocks with Warning Signs
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
News headline image
Evolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
News headline image
3 of Wall Street’s Favorite Stocks in Hot Water
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
News headline image
Myriad Genetics Earns 2025 Great Place To Work Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
News headline image
3 High-Flying Stocks Facing Headwinds
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
Topics Malware
News headline image
3 Stocks Under $10 in the Doghouse
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
News headline image
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via... 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Cash-Burning Stocks Facing Headwinds
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. 
Via StockStory
News headline image
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story